Obesity Paradox For Stroke In Patients With Atrial Fibrillation Treated With Rivaroxaban And Warfarin In The Rocket Af Trial

Somasekhara R Balla,Derek D Cyr,Yuliya Lokhnygina,Richard C Becker,Scott D Berkowitz,Guenter Breithardt,Robert M Califf,Keith A A Fox,Werner Hacke,Jonathan L Halperin,Graeme J Hankey,Kenneth W Mahaffey,Christopher C Nessel,Jonathan P Piccini,Daniel E Singer,Manesh R Patel

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2014）

Cited 5|Views14

No score

Abstract

Obesity is a risk factor for development of atrial fibrillation (AF). The impact on stroke outcomes in patients with AF is unknown. We investigated stroke outcomes in normal weight ([NW] BMI 18.50-24.99 kg/m2), overweight ([OW] BMI 25.00-29.99kg/m2), and obese ([OB] BMI ≥30 kg/m2) patients with AF

Translated text

Key words

atrial fibrillation,rivaroxaban,warfarin,stroke

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined